Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 14 March 2024, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator carries out a rights issue of units of approximately SEK 150.9 million with an over-allotment issue of up to an additional approximately SEK 100.0 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience AB reports full year financial results for 2023 and for Q4 2023 and provides a business update
Mitazalimab meets OPTIMIZE-1 Phase 2 primary endpoint, demonstrating 40.4% Overall Response Rate and median Overall Survival of 14.3 months ...
Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation
Expected annual cash savings of SEK 20 million Restructuring follows successful conclusion of resource intensive OPTIMIZE-1 Phase 2 trial Fo ...
Alligator Bioscience Announces Positive Mitazalimab OPTIMIZE-1 Phase 2 Results Meeting Primary Endpoint and Demonstrating Clinically Relevant Survival Benefits in 1st Line Pancreatic Cancer
Top-line readout demonstrates Objective Response Rate of 40.4%, meeting primary endpoint and confirming the benefit of mitazalimab in combin ...
Correction: Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB
The press release as of November 6, 2023 regarding the Nomination Committee appointed in respect of AGM 2024 incorrectly stated Hans-Peter O ...
Nomination Committee appointed in respect of AGM 2024 in Alligator Bioscience AB
Lund, Sweden, November 6, 2023– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation ...
Alligator Bioscience AB reports financial results for the first 9 months of 2023 and for Q3 2023 and provides a business update
European Medicines Agency grants mitazalimab Orphan Designation in pancreatic cancer Technical Feasibility achieved in second collaboration ...